Last reviewed · How we verify
BXCL701
BXCL701 is a selective inhibitor of sphingosine-1-phosphate receptor 1 (S1P1) that modulates immune cell trafficking and reduces pathological inflammation.
BXCL701 is a selective inhibitor of sphingosine-1-phosphate receptor 1 (S1P1) that modulates immune cell trafficking and reduces pathological inflammation. Used for Systemic lupus erythematosus (SLE).
At a glance
| Generic name | BXCL701 |
|---|---|
| Also known as | Talabostat |
| Sponsor | Eric Stephen Winer, MD |
| Drug class | S1P1 receptor modulator |
| Target | S1P1 (Sphingosine-1-phosphate receptor 1) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
S1P1 inhibition prevents lymphocyte egress from secondary lymphoid organs, reducing circulating lymphocyte counts and dampening aberrant immune responses. This mechanism is thought to be beneficial in autoimmune and inflammatory conditions by sequestering autoreactive lymphocytes in lymph nodes and spleen, thereby reducing their infiltration into affected tissues.
Approved indications
- Systemic lupus erythematosus (SLE)
Common side effects
- Lymphopenia
- Headache
- Infection
Key clinical trials
- BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PHASE2)
- A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. (PHASE1, PHASE2)
- BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome (PHASE1)
- Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers (PHASE2)
- Talabostat in Treating Patients With Metastatic Kidney Cancer (PHASE2)
- A Pilot Study of BXCL701 in Patients With Pancreatic Cancer (EARLY_PHASE1)
- Efficacy and Physiology of Nasal High Flow Therapy (NA)
- Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BXCL701 CI brief — competitive landscape report
- BXCL701 updates RSS · CI watch RSS
- Eric Stephen Winer, MD portfolio CI